Skip to main content
SpringerLink
Log in

Tumormarker — ihre Bedeutung für Diagnostik und Verlaufskontrolle des Bronchialkarzinoms

  • Chapter
Thoraxtumoren

  • 33 Accesses

Zusammenfassung

Unter Tumormarkern versteht man Substanzen, die bei bestehendem malignen Leiden in erhöhter Konzentration in Körperflüssigkeiten vorkommen oder verstärkt zellulär exprimiert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arroliga AC, Matthay RA (1993) The role of bronchoscopy in lung cancer. Clinics Chest Med 14: 87–89

    CAS  Google Scholar 

  • Bergman B, Brezicka F, Eneström C (1992) Clinical utility of serum assays of neuronspecific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnostic evaluation of lung cancer patients. Eur J Cancer 29: 198–202

    Article  Google Scholar 

  • Body JJ, Sculier JP, Raymakers N, Paesmans H, Ravez P, Libert P, Richez M, Dabouis G, Lacroix H, Bureau G (1990) Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer 65: 1552–1556

    Article  PubMed  CAS  Google Scholar 

  • Büttner J (1977) Die Beurteilung des diagnostischen Wertes klinisch-chemischer Untersuchungen. J Clin Chem Clin Biochem 15: 1–12

    PubMed  Google Scholar 

  • Byrd RB, Carr DT, Miller WE, Payne WS, Woolner LB (1969) Radiographic abnormality in carcinoma of the lung as related to histological cell type. Thorax 24: 573–575

    Article  PubMed  CAS  Google Scholar 

  • Colby TV, Hoppe RT, Warnke RA (1981) Hodgkin’s disease: A clinicopathologic study of 659 cases. Cancer 49: 1848–1858

    Article  Google Scholar 

  • Costongs GMBJ, Janson PCW, Bas BM, Hermans J, Brombacher PJ, van Wersch JWJ (1985) Short-term and long-term intra-individual variation and citical difference of haematological laboratory parameters. J Clin Chem Clin Biochem 23: 69–76

    PubMed  CAS  Google Scholar 

  • Cox D (1972) Regression models and life tables. SR Statist Soc B 34: 187–202

    Google Scholar 

  • Ebert W, Stabrey A, Bülzebruck H, Kayser K, Merkle N (1988) Efficiency of SCC antigen determination for diagnosis and therapy-monitoring of squamous cell carcinoma. Tumor Diagn Ther 9: 87–95

    Google Scholar 

  • Ebert W, Hug G, Stabrey A, Bülzebruck H, Drings P (1989) Evaluation of tumour markers NSE and CEA for tne diagnosis and follow-up of small cell lung cancer. Ärztl Lab 35: 1–10

    Google Scholar 

  • Ebert W, Stabrey A, Sibinger M, Schrenk M (1991) Value of pleural fluid hyaluronic acid and carcinoembryonic antigen determinations in the differential diagnosis between malignant mesothelioma and pleuritis carcinomatosa. Tumor Diagn Tner 12: 1–6

    Google Scholar 

  • Ebert W, Leichtweis B, Bülzebruck H. Drings P (1992) The role of IMx SCC assays in the detection and prognosis of primary squamous-cell carcinoma of the lung. Diagn Oncol 2: 203–210

    Google Scholar 

  • Ebert W, Leichtweis B, Schapöhler B, Muley Th (1993 a) The New Tumor Marker CYFRA is Superior to SCC antigen and CEA in the primary diagnosis of lung cancer. Tumor Diagn Ther 14: 91–99

    Google Scholar 

  • Ebert W, Muley Th, Wassenberg D (1993 b) NSE in the primary diagnosis of small cell lung cancer. Comparison of the DELFIA NSE with the RIA technique. Tumor Diagn Ther 14: 61–65

    Google Scholar 

  • Ebert W, Schleifer A, Bülzebruck H (1993 c) Usefullness and limits or tumor marker assays in pleural effusions. Tumor Diagn Ther 14: 147–151

    Google Scholar 

  • Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E (1994) Cytokeratin 19 fragment CYFRA 21-1 compared wirh carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 32: 189–199

    PubMed  CAS  Google Scholar 

  • Ebert W, Bodenmüller H. Holzel W (1995) CYFRA 21-1 Medical decision-making and analytical standardization and requirements. Scand J Clin Lab Invest 55 Suppl. 221: 72–80

    Article  CAS  Google Scholar 

  • Ebert W, Ryll R, Muley Th, Hug D, Drings P (1996) Do neuron-specific enolase levels dis-criminate between small-cell lung cancer and mediastinal tumors? Tumor Biol 17: 362–368

    Article  CAS  Google Scholar 

  • Ebert W, Hoppe M, Muley T, Drings P (1997) Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA-M, TPS, CEA and NSE. Anticancer Res 17: 2875–2878

    PubMed  CAS  Google Scholar 

  • Filella X, Cases A, Molina R et al. (1990) Tumor markers in patients with chronic renal failure. Int J Biol Markers 5: 85–88

    PubMed  CAS  Google Scholar 

  • Grunze H (1964) The comparative diagnostic accuracy, efficiency and specificity of cytologic techniques used in the diagnosis of malignant neoplasm in serous effusions of the pleural and pericardial cavities. Acta Cytol 8: 150–164

    PubMed  CAS  Google Scholar 

  • Holzel WGE, Beer R, Deschner W, Griesmacher A, Müller MM (1995) Individual reference ranges of CA 15-3, MCA and CEA in recurrence of breast cancer. Scand J Clin Lab Invest Suppl 55 221: 93–101

    Article  Google Scholar 

  • Jorgensen LGM, Osterlind K, Hansen HH, Cooper EH (1988) The prognostic influence of serum neuron-specific enolase in small cell lung cancer. Br J Cancer 58: 805–807

    Article  PubMed  CAS  Google Scholar 

  • Mehta AC, Marty JJ, Lee FYW (1993) Sputum cytology. Clinics Chest Med 14: 69–85

    CAS  Google Scholar 

  • Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N, Ballesta AM (1994) Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumor Biol 15: 318–325

    Article  CAS  Google Scholar 

  • Müller KM (1989) Morphologische Diagnostik. In: Nakhosteen JA, Niederle Z, Zavala DC (Hrsg.) Atlas und Lenrbucn der Bronchoskopie. Springer, Berlin Heidelberg New York, S. 94–126

    Google Scholar 

  • Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J (1995) Diagnostic and prognostic value of the new tumor marker CYFRA 21-1 in patients with squamous lung cancer. Eur Resp J 8: 291–294

    Article  CAS  Google Scholar 

  • Oehr P, Lütghens ML, Liu Q (1992) Tissue polypetide antigen and specific TPA. In: Sell S (ed) Serological cancer markers. Humana, Tolowa, NJ, pp 193–206

    Chapter  Google Scholar 

  • Paone G, De Angelis G, Munno R, Pallotta G, Bigioni D, Saltini C, Bisetti A, Ameglio F (1995) Discriminant analysis on small cell lung cancer by means of NSE and CYFRA 21-1. Eur Respir J 8: 1136–1140

    Article  PubMed  CAS  Google Scholar 

  • Pujol J-L, Grenier J, Daures J-P, Daver A, Pujol H, Michel F-B (1993) Serum fragment of cytokeratin subunit 19 measured by cytokeratin 19 fragment CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61–66

    PubMed  CAS  Google Scholar 

  • Pujol J-L, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X, Michel F-B (1996) Cytokeratins as serum markers in lung cancer: A comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 154: 725–733

    PubMed  CAS  Google Scholar 

  • Rastel D, Ramaioli A, Cornillie F, Thirion B (1994) CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Rep 1st Eur Multicenter evaluation. Eur J Cancer 30A: 601–606

    Google Scholar 

  • Romero S, Fernandez C, Arriero JM, Espasa A, Candela A, Martin C, Paya-Sanchez J (1996)CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 9: 17–23

    Article  PubMed  CAS  Google Scholar 

  • Stieber P, Dienemann H, Hasholzner U, Müller C, Poley S, Hofmann K, Fateh-Moghadam A (1993) Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 31: 689–694

    PubMed  CAS  Google Scholar 

  • Touitou Y, Bogdan A (1988) Tumor markers in non-malignant diseases. Eur J Cancer Clin Oncol 24: 1083–1091

    Article  PubMed  CAS  Google Scholar 

  • Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornilie F, Splinter TAW (1994) Evaluation of a new tumour marker in patients with non-small-cell lung cancer: CYFRA 21-1. Br J Cancer 69: 525–528

    Article  PubMed  Google Scholar 

  • Whitaker D, Shilkin KB, Stucky M, Nieuwhof WN (1986) Pleural fluid levels in the diagnosis of malignant mesothelioma. Pathology 18: 328–329

    Article  PubMed  CAS  Google Scholar 

  • WHO — World Health Organization (1979) Handbook of reporting results of cancer treatment. WHO, Geneva, Offset Publ 48 WHO — World Health Organization ( 1981 ) Histological classification of lung tumours. WHO, Geneva

    Google Scholar 

Download references

Authors
  1. W. Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Muley
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin/Onkologie, Thoraxklinik Heidelberg-Rohrbach der Landesversicherungsanstalt Baden, Amalienstr. 5, 69126, Heidelberg, Germany

    P. Drings

  2. Ziegelhäuser Landstraße 65, 69117, Heidelberg, Germany

    I. Vogt-Moykopf

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ebert, W., Muley, T. (1998). Tumormarker — ihre Bedeutung für Diagnostik und Verlaufskontrolle des Bronchialkarzinoms. In: Drings, P., Vogt-Moykopf, I. (eds) Thoraxtumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72041-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72041-3_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72042-0

  • Online ISBN: 978-3-642-72041-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation